Drug Newswire
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.
This page shows you the latest items in this publication.
Pharmos Completes Phase 1 Study of Topical Diclofenac NanoEmulsion Cream
Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Data Indicate Positive Results Achieved on Safety, Tolerability and Pharmacokinetics
ISELIN, N.J., Nov. 14 /PRNewswire-FirstCall/ -- Pharmos Corporation (NASDAQ:PARS) announced today it has completed its initial analysis of data from a recently completed Phase 1 study of its proprietary NanoEmulsion topical drug delivery technology formulated with diclofenac. Diclofenac...
Source: Drug Newswire - April 11, 2007 Category: Pharmaceuticals Source Type: news
Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and LymphomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
SOUTH SAN FRANCISCO, Calif., April 11 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today provided a clinical update on R788, which is currently in ongoing Phase 2 clinical trials in immune thrombocytopenic purpura (ITP), rheumatoid arthritis (RA) and lymphoma patients. R788 is a novel, oral syk kinase inhibitor that blocks the...
Source: Drug Newswire - April 11, 2007 Category: Pharmaceuticals Source Type: news
Neurochem's eprodisate (KIACTA(TM)) PDUFA date extended three months by FDAEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
ECUBLENS, Switzerland, April 11 /PRNewswire-FirstCall/ -- Neurochem (International) Limited (Neurochem), a wholly owned subsidiary of Neurochem Inc. (NASDAQ: NRMX; TSX: NRM), announces that it received notification from the United States Food and Drug Administration (FDA) that the action date for FDA's review of the New Drug Application (NDA) for eprodisate...
Source: Drug Newswire - April 11, 2007 Category: Pharmaceuticals Source Type: news
WellGen Completes Human Study Paving Way for Nutrigenomics to Play Important Role in Mainstream Product DevelopmentEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
NEW BRUNSWICK, N.J., April 10 /PRNewswire/ -- WellGen, Inc. today announced that it has completed a pivotal study demonstrating that its nutrigenomics technology platform can successfully predict biological activity of natural products in humans. WellGen is a biotechnology company that uses nutrigenomics to discover and develop proprietary functional food ingredients.
Source: Drug Newswire - April 11, 2007 Category: Pharmaceuticals Source Type: news
Pharmacopeia Announces Positive Results from Initial DARA Clinical TrialEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
PS433540 Shown to Be Well Tolerated and Potentially Suited for Once Daily Administration
PRINCETON, N.J., April 10 /PRNewswire-FirstCall/ -- Pharmacopeia (NASDAQ:PCOP) , an innovator in the discovery and development of novel small molecule therapeutics, today announced positive results from the initial Phase 1 clinical trial of PS433540, the...
Source: Drug Newswire - April 11, 2007 Category: Pharmaceuticals Source Type: news
New Clinical Study on Clarinol(TM) CLA Confirms Regional-Specific Fat Mass Decrease in Overweight and ObeseEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
New insights with six month trial with Clarinol(TM) CLA and its effect on weight management
CHANNAHON, Ill., April 9 /PRNewswire/ -- This month the British Journal of Nutrition revealed its latest results on Clarinol(TM) CLA. New research shows that Clarinol(TM) CLA reduces fat mass in particular locations on...
Source: Drug Newswire - April 11, 2007 Category: Pharmaceuticals Source Type: news
Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival Benefits as Mitigator Against Radiation-Induced Damage in StudyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Chief Scientist to Present Results at 2007 American Association for Cancer Research Annual Meeting
First Compound to Protect from both Gastrointestinal and Hematopoietic Damage when Administrated before or after Irradiation
CLEVELAND, April 9 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI) , announced today the results of its...
Source: Drug Newswire - April 11, 2007 Category: Pharmaceuticals Source Type: news
Probiotics Offer a Natural Option for IBS SufferersEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Millions of Americans now seeking a safe, effective alternative treatment for IBS
CINCINNATI, April 9 /PRNewswire/ -- With the recent Food and Drug Administration discontinuation of a leading prescription drug for constipation associated with irritable bowel syndrome (IBS) and chronic constipation, millions of Americans are now seeking a...
Source: Drug Newswire - April 11, 2007 Category: Pharmaceuticals Source Type: news
Memory Pharmaceuticals Completes Enrollment in Phase 2a MEM 1003 Alzheimer's Disease TrialEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
MONTVALE, N.J., April 5 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) today announced that it has completed enrollment in its Phase 2a trial of MEM 1003 in Alzheimer's disease. The Company expects to report top-line results for this trial in the fourth quarter of 2007.
"Completion of enrollment in...
Source: Drug Newswire - April 11, 2007 Category: Pharmaceuticals Source Type: news
Michigan Lutherans Dispose of Hazardous Waste on Earth DayEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
MARQUETTE, Mich., April 3 /PRNewswire-USNewswire/ -- For the third year in a row, thousands of Lutherans will turn in hazardous waste during the annual Earth Keeper Clean Sweep on Earth Day, April 22, at collection sites across northern Michigan. This year the target is pharmaceuticals.
Members of the...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Osteologix Appoints Philip J. Young President and Chief Executive OfficerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
SAN FRANCISCO, April 3 /PRNewswire-FirstCall/ -- Osteologix Inc. (BULLETIN BOARD: OLGX) announced today that it has appointed Philip J. Young as President and Chief Executive Officer, effective May 1, 2007. Mr. Young most recently was Chief Business Officer, Executive Vice President of Insmed, Inc. Previously he has served as an...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone TherapyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
COLLEGEVILLE, Pa., April 3 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE) , provides comment on a re- analysis of pooled data from both hormone therapy arms of the Women's Health Initiative (WHI) Study published today in the Journal of the American Medical Association. The pooled analysis showed no...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Hardinge Announces Follow-On Stock OfferingEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
ELMIRA, N.Y., April 3 /PRNewswire-FirstCall/ -- Hardinge Inc. (NASDAQ:HDNG) , a leading global provider of advanced material-cutting solutions, today announced that it commenced an underwritten public offering of 1,650,000 shares of common stock from its existing shelf registration statement. The underwriters have been granted an over-allotment option to purchase an...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Pharmacyclics to Host Conference Call on Wednesday, April 4, 2007Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
SUNNYVALE, Calif., April 3 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (NASDAQ:PCYC) today announced that it will hold a conference call on Wednesday, April 4, 2007, at 9:00 a.m. EST (6:00 a.m. PST) to discuss company news.
To participate in the conference call, please dial 800-497-0451 for domestic callers and 706-758-3306...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Thermo Fisher Scientific Completes Sale of GenevacEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
WALTHAM, Mass., April 3 /PRNewswire-FirstCall/ -- Thermo Fisher Scientific Inc. (NYSE:TMO) , the world leader in serving science, today announced that it has completed the sale of its Genevac business, a manufacturer of vacuum concentrators, to private equity firm Riverlake Equity Partners, LP. Riverlake intends to eventually merge Genevac into...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
PCMA: National, Uniform Electronic-Prescribing Standard Needed to Increase Physician AdoptionEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
WASHINGTON, April 3 /PRNewswire-USNewswire/ -- With a survey of group practices finding physicians face cultural and infrastructural barriers to adoption of electronic-prescribing technology -- including uncertainty over state regulation in some markets -- the Pharmaceutical Care Management Association (PCMA) today reiterated its call for a national, uniform electronic prescribing (e-prescribing)...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Centrix Pharmaceutical Chooses Cegedim's Target SFA for Sales Force EffectivenessEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
ALLENTOWN, Pa., April 3 /PRNewswire/ -- Cegedim North America announced today that Centrix Pharmaceutical of Birmingham, Alabama, has agreed to license and deploy the Target SFA customer relationship management suite for its U.S. sales force. Centrix will use both the Windows Mobile(TM) and web versions of Target Mobile to automate...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Angiotech's Corporate Partner, Boston Scientific, announces Japanese approval for the TAXUS(R) Express2(TM) stent systemEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
VANCOUVER, April 3 /PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI) (NASDAQ:TSX:) (NASDAQ:ANP) , a global specialty pharmaceutical and medical device company, along with its corporate partner, Boston Scientific Corporation (NYSE:BSX) , announced today that Boston Scientific has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to market...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Soligie's New Printed Electronics Manufacturing FacilityEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
MINNEAPOLIS, April 3 /PRNewswire/ -- Soligie, a market leader providing integrated printed electronic solutions, announced today the scheduled opening of their new state of the art printed electronics manufacturing facility.
Soligie continues to expand its capacity to meet the growing demand for integrated printed electronic solutions. The new...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
AARP Calls on U.S. Senate to Take a StandEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Group Wages Nationwide Campaign to Help Lower Medicare Drug Prices
WASHINGTON, April 3 /PRNewswire-USNewswire/ -- With the aid of its 38 million members, AARP is calling on the U.S. Senate to stand with the overwhelming majority of Americans and vote to give Medicare the power to negotiate for...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
closerlook Celebrates 20th Anniversary as one of Chicago's Internet Success StoriesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CHICAGO, April 3 /PRNewswire/ -- closerlook, an innovative communication and relationship marketing company, Internet pioneer, and successful survivor of the early 21st century "tech wreck" celebrates 20 years in business this April 6, 2007. The company has developed unique technology-driven marketing solutions for leading Fortune 500 companies in a host...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
PPD Announces First Quarter 2007 Earnings Release, Webcast and Conference CallEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
WILMINGTON, N.C., April 3 /PRNewswire-FirstCall/ -- PPD, Inc. (NASDAQ:PPDI) will release its first quarter 2007 financial results on Tuesday, April 17, after the market closes. The earnings release will be available on the PPD Web site at http://www.ppdi.com/, FirstCall and PR Newswire.
On Wednesday, April 18,...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Lilly Announces Completion of Hypnion AcquisitionEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
INDIANAPOLIS, April 3 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE:LLY) today announced that it has completed its acquisition of Hypnion, Inc., a privately held neuroscience drug discovery company focused on sleep disorder research.
The deal, valued at a total purchase price of $315 million, bolsters Lilly's pipeline with...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Assured Pharmacy Reports Record Year-End ResultsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
2006 Revenues Increase 106%; Operating Loss Decreases 29%
IRVINE, Calif., April 3 /PRNewswire-FirstCall/ -- Assured Pharmacy, Inc. (BULLETIN BOARD: APHY) today announced financial results for the Company's twelve months ended December 31, 2006. Revenue for 2006 increased 106%, to $7.9 million, from $3.8 million in 2005, with the...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Robert B. Stein, M.D., Ph.D., Joins Archemix Board of DirectorsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CAMBRIDGE, Mass., April 3 /PRNewswire/ -- Archemix Corp. announced today that Robert B. Stein, M.D., Ph.D., has been appointed to the company's Board of Directors.
Dr. Stein brings to Archemix over 25 years of experience in research and development and business roles with pharmaceutical and biotechnology companies. From...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
New 'Targeted' Treatments Improve Colon Cancer Survival RatesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Avastin, Avemar, Boost Conventional Treatment Efficacy, Survival
BLAUVELT, New York, April 3 /PRNewswire/ -- People diagnosed with advanced colorectal cancer that has spread to distant organs, such as White House spokesman Tony Snow, are much more likely to survive today than even just a few years ago, due...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
China Biopharmaceuticals Holdings Announces Fiscal Year 2006 Financial ResultsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
BEIJING, April 3 /Xinhua-PRNewswire-FirstCall/ -- China Biopharmaceuticals Holdings, Inc. (BULLETIN BOARD: CHBP) , a leading Chinese pharmaceutical company focused on the development, manufacturing and marketing of innovative drugs in China, today announced its financial results for the year ended December 31, 2006.
Revenues for the year ended December...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Pharma CRM Bulletin: New Study Emphasizes the Importance of Defining CRM and Internal EducationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
RESEARCH TRIANGLE PARK, N.C., April 3 /PRNewswire/ -- A new study released by Cutting Edge Information found that many pharmaceutical CRM initiatives suffer from the lack of a firm definition. The report, available at http://pharmaindustrycrm.com/, focuses on the inner-workings and best practices of CRM initiatives at top pharmaceutical...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Video: Introducing Bayer Nutritional Science(TM) - New Nutritional Supplement Line from Bayer HealthCareEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Benefit-Focused Line to Answer Needs of Vital, Active Boomers
MORRISTOWN, N.J., April 3 /PRNewswire/ -- Bayer HealthCare announces the introduction of Bayer Nutritional Science(TM), a new line of nutritional supplements that unites science and nutrition to help active Baby Boomers maximize their vitality. The Bayer Nutritional Science(TM) line...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Archi-Tech Launches Interactive Reporting Portal for Pharmaceutical Sales, Marketing, and Managed Care DataEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
InView Delivers a Dashboard of Key Performance Indicators, Dynamic Graphs, and Custom Metrics to Drive Sales Planning and Reporting
WEST TRENTON, N.J., April 3 /PRNewswire/ -- Archi-Tech Systems, a leader in pharmaceutical data analysis and reporting solutions, today announced the launch of InView, an interactive reporting portal offering...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Aida Pharmaceuticals Reports Fiscal 2006 Year End ResultsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
- Net Income Up 89% Excluding Non-recurring Item -
HANGZHOU, China, April 3 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (BULLETIN BOARD: AIDA) , one of mainland China's leading pharmaceutical companies, today announced its financial results for the fiscal year ended December 31, 2006. Excluding a non-recurring, non-cash expense of...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Codexis Expands Senior Management TeamEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
REDWOOD CITY, Calif., April 3 /PRNewswire/ -- Codexis, Inc., a private biotechnology company, today announced expansion of its senior management team with the addition of two new positions. Joseph Sarret, M.D., J.D. has been named Vice President, Corporate Development and Douglas Sheehy, J.D. has been appointed Vice President, General Counsel...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Pharmasset Announces Clevudine and Hepatitis C Presentations at EASLEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The 42nd Annual Meeting of the European Association for the Study of the Liver
PRINCETON, N.J., April 3 /PRNewswire/ -- Pharmasset announced today that presentations of preclinical studies of Clevudine for the treatment of hepatitis B (HBV) and PSI-6130, the parent molecule of R7128, for the treatment of...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
New Data Show Early Non-Response to Antipsychotic Treatment May Be Strong Predictor of Subsequent Non-Response for People with SchizophreniaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Findings indicate early non-responders unlikely to subsequently respond, have substantially more treatment costs, and may benefit from earlier change in treatment strategy
COLORADO SPRINGS, Colo., April 3 /PRNewswire-FirstCall/ -- New data presented at the 2007 International Congress on Schizophrenia Research (ICOSR) suggest that antipsychotic drug response be assessed...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Angiotech appoints Chris Dennis as Senior Vice President, Sales and MarketingEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
VANCOUVER, April 3 /PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI) (NASDAQ:TSX:) (NASDAQ:ANP) , a global specialty pharmaceutical and medical device company, today announced the appointment of Chris Dennis as Senior Vice President, Sales and Marketing.
Mr. Dennis brings to Angiotech a broad background in marketing, sales and general management...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Onmark Signs Exclusive Contracts with Pfizer and Berlex for Oncology and Supportive Care ProductsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Only GPO to Offer These Contracts in the Marketplace -
SOUTH SAN FRANCISCO, Calif., April 3 /PRNewswire/ -- Onmark, a national group purchasing organization (GPO) for community-based practices and an OTN company, today announced that it has signed new contracts with Pfizer for Camptosar(R) (irinotecan) and with Berlex...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
MediVas Announces Achievement of Milestone in Connection With Merck AgreementEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
SAN DIEGO, April 3 /PRNewswire/ -- MediVas, LLC, a developer of novel drug delivery platforms, today announced the achievement of a milestone relating to its previously disclosed agreement with Merck & Co., Inc. The milestone was specifically connected to one of the several orally available biologics that are the focus...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Wyeth Completes Purchase of Wyeth K.K. JapanEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
MADISON, N.J., April 3 /PRNewswire-FirstCall/ -- Wyeth (NYSE:WYE) today announced the purchase of the final 20 percent stake of Wyeth K.K. (WKK), from Takeda Pharmaceuticals Company Limited (Takeda), bringing Wyeth's ownership interest in WKK to 100 percent. Wyeth entered into an Equity Transfer Agreement with Takeda in May 2003. Financial...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Codexis and Merck Sign Technology CollaborationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Merck Becomes First Subscriber to Codex(TM) Biocatalyst Panels, Next-Generation Technology Driving Early Stage Adoption Of Custom Biocatalysts by Pharma Manufacturers
REDWOOD CITY, Calif., April 3 /PRNewswire/ -- Codexis, Inc., a private biotechnology company, today announced a significant technology collaboration with Merck & Co., Inc. under which Merck will...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
New River Pharmaceuticals Inc. Announces Convertibility of 3.50% Convertible Subordinated Notes Due 2013Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
RADFORD, Va., April 3 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (NASDAQ:NRPH) today announced that, in connection with its previously disclosed pending acquisition by Shire plc pursuant to a "first-step" cash tender offer for all outstanding New River shares at $64.00 per share followed by a "second-step" cash merger at the...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Nipent(R) Acquisition by Hospira is CompleteEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
DUBLIN, Calif., April 3 /PRNewswire-FirstCall/ -- SuperGen Inc. (NASDAQ:SUPG) today announced that it closed on the sale of the remaining worldwide rights for Nipent(R) (pentostatin for injection) to Mayne Pharma, which was acquired in February 2007 by Hospira, for a total consideration of US$8 million. SuperGen received an initial up-front...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Frost & Sullivan Commends Altea Therapeutics for Extending the Frontiers of Transdermal Drug DeliveryEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
PALO ALTO, Calif., April 3 /PRNewswire/ -- Frost & Sullivan has presented Atlanta-based Altea Therapeutics with the 2007 Frost & Sullivan Technology Innovation Award in the field of transdermal drug delivery for its development of the PassPort(TM) System, a new breakthrough technology that enables painless delivery through the skin of...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
PHM International Launches Emerging Markets Healthcare MonitorEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
SEBASTIAN, Fla., April 3 /PRNewswire/ -- PHM International, Inc. a worldwide healthcare consultancy is pleased to announce the launch of PHM Emerging Markets Healthcare Monitor -- the only professional trade publication devoted exclusively to key healthcare/life sciences sector developments in transactions and regulatory change in emerging markets/economies.
Available...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
NicOx Initiates Second Phase 3 Study to Confirm Naproxcinod's Efficacy and Improved Blood Pressure ProfileEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
SOPHIA ANTIPOLIS, France, April 3 /PRNewswire/ -- NicOx S.A. (Eurolist: COX) today announced that it has initiated the second pivotal phase 3 trial for naproxcinod in patients with osteoarthritis of the knee (the 302 study). The trial is expected to enroll approximately 1020 patients at around 120 clinical centers in...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Alliance Pharmaceutical Corp. Provides Company UpdateEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
SAN DIEGO, April 2 /PRNewswire-FirstCall/ -- Alliance (BULLETIN BOARD: ALLP) today announced that it held two teleconferences with the holders of its outstanding Senior Convertible Promissory Notes ("Senior Notes"). The first teleconference took place on March 30, 2007. This teleconference was repeated on April 2, 2007.
In connection...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Ardea Biosciences, Inc. Reports 2006 Financial ResultsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CARLSBAD, Calif., April 2 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. ("Ardea" or the "Company") (Pink Sheets: ARDC) today reported financial results for the fourth quarter and twelve months ended December 31, 2006.
Ardea reported a net loss applicable to common stockholders of $476,000, or $0.05 per basic and diluted...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Dragon Pharmaceutical Announces 2006 Year End ResultsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
VANCOUVER, April 2 /PRNewswire-FirstCall/ -- Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG; BBSE: DRP) today announced the results for its fiscal year ended December 31, 2006. As previously disclosed, Dragon sold a part of its formulation business effective July 1, 2006, therefore the financial results of 2005 were reclassified...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
3SBio Inc. Announces Fourth Quarter And Fiscal Year 2006 ResultsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
- Q4 2006 net revenues grew 36.0%, as compared to Q4 2005, to US$4.5 million
- Q4 2006 operating income up 148.1%, as compared to Q4 2005, to US$1.1 million
- 2006 fiscal year net revenues increased 25.3% year-over-year to US$16.4 million
- 2006...
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
Genelabs Technologies Receives Agreement From FDA on Special Protocol Assessment for Phase III Trial of Prestara in LupusEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
REDWOOD CITY, Calif., April 2 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (NASDAQ:GNLB) announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase III clinical trial of Prestara(TM) (prasterone) for treatment of systemic lupus erythematosus (lupus).
Source: Drug Newswire - April 5, 2007 Category: Pharmaceuticals Source Type: news
